Evidence map›Paper›PMID 21647742›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2012

The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer.

Lucia M A Crane, Henriette J G Arts, Marleen van Oosten, Philip S Low, Ate G J van der Zee, Gooitzen M van Dam, Joost Bart

Erratum issued Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02317705 (A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection), which is not on this map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02317705 phase2completednot on this mapstarted 2014, after this paper: background citation

A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer

TypeinterventionalSponsorOn Target Laboratories, LLCRan2014 to 2015Enrolled48ConditionsOvarian CancerArmsOTL38, Near infrared camera imaging system, Laparotomy
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2025
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Emerging roles for folate receptor FOLR1 in signaling and cancer.Trends in endocrinology and metabolism: TEM · 2022
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Lucia M A CraneDepartment of Surgery, Division of Surgical Oncology, University of Groningen, [corrected] University Medical Center Groningen, Groningen, the Netherlands.
Henriette J G Arts
Marleen van Oosten
Philip S Low
Ate G J van der Zee
Gooitzen M van Dam
Joost Bart
University Medical Center Groningen · NLPurdue University West Lafayette · USTarget (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFolate receptor alpha (FR-α) has been identified as a potential target in ovarian cancer for diagnostic and therapeutic purposes, based on its overexpression in serous epithelial ovarian carcinoma. The effect of chemotherapy on FR-α expression may be important in the applicability of FR-α directed agents in the case of residual tumor tissue. The objective of this study was to assess FR-α expression in ovarian carcinoma and to evaluate whether FR-α expression is altered by chemotherapy. MATERIALS &

methodsFR-α expression was analyzed by semi-quantitative scoring of immunohistochemical staining on tissue microarrays (TMAs) from a database containing 361 ovarian cancer tissue samples, of which 210 serous and 116 non-serous carcinoma (35 missing). Serous carcinoma samples included 28 matched samples with tissue from both primary surgery and interval debulking surgery, and 12 matched samples with tissue from both primary surgery and surgery for recurrent disease.

resultsFR-α expression was seen in 81.8% of serous ovarian cancers versus 39.9% of non-serous carcinomas (p < 0.001). In matched serous carcinoma samples, no significant change in FR-α expression in vital tumor tissue after chemotherapy was observed (p = 0.1). FR-α expression was not a prognostic marker of progression free survival (p = 0.8) or overall survival (p = 0.7).

conclusionFR-α was expressed in the majority of serous ovarian tumors, although >50% of cases showed only weak expression. Chemotherapy did not alter expression rates in remaining vital tumor tissue, indicating that folate-targeted agents may have a place in the treatment for ovarian cancer, before as well as after chemotherapy. Furthermore, FR-α status did not influence survival.

Indexed as

AdolescentAdultAgedAged, 80 and overAntineoplastic AgentsDisease-Free SurvivalFemaleFolate Receptor 1HumansMiddle AgedMultivariate AnalysisNeoplasms, Cystic, Mucinous, and SerousOvarian NeoplasmsProportional Hazards ModelsYoung AdultAntineoplastic AgentsFolate Receptor 1FOLR1 protein, human

Identifiers

PMID21647742
PMCPMC3268989
OpenAlexW2051980540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.